TRPC1 and Parkinson disease: As L-type calcium channel blockers like isradipine have already gone into clinical trials for PD, TRPC1 performing the same physiological function in dopaminergic neurons could be looked at as a molecular target in PD (Simuni et al., 2010; Sun et al., 2017).